At a glance
ClinicalIndex Comparison RecordPhase 3Active· 180 target
Drug / intervention
CM310biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of CM310 in Adolescent Patients With Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating CM310 for Atopic Dermatitis. Active but no longer recruiting, targeting 180 participants across 1 site.
Detailed Summary
This is a multi-center, single arm, open label phase 3 study to evaluate the safety and efficacy of CM310 in children patients with moderate-to-severe atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesChina
Collaborators--
Timeline
Phase 3Active
20252026
First PostedJul 2024
Enrollment StartAug 2024
TodayJul 2026
Primary CompletionAug 2026
First PostedJul 10, 2024
Enrollment StartAug 2, 2024
Primary CompletionAug 30, 2026
TodayJul 1, 2026
Enrollment to primary: 2.1 yearsPosted 2.0 years agoPrimary completion in 2 months
Interventions
CM310biological
Interleukin-4 receptor(IL-4Rα) monoclonal antibody